ImmuPharma crashes 85% as Phase III lupus trials flop
Shares in drug discovery company ImmuPharma (IMM:AIM) collapsed on Tuesday demonstrating just how risking early stage drug development really is. The company's lead drug Lupuzor failed to show meaningful statistical benefits over...
17 April 2018